Circulating tumour cells and cancer stem cells: A role for proteomics in defining the interrelationships between function, phenotype and differentiation with potential clinical applications

2013 ◽  
Vol 1835 (2) ◽  
pp. 129-143 ◽  
Author(s):  
Roberto Scatena ◽  
Patrizia Bottoni ◽  
Bruno Giardina
Keyword(s):  
Stem Cells ◽  
Cancer Stem Cells ◽  
Clinical Applications ◽  
Tumour Cells ◽  
Circulating Tumour Cells

Rapid reprogramming of tumour cells into cancer stem cells on double-network hydrogels

2021 ◽  
Author(s):  
Jun Suzuka ◽  
Masumi Tsuda ◽  
Lei Wang ◽  
Shinji Kohsaka ◽  
Karin Kishida ◽  
...  
Keyword(s):  
Stem Cells ◽  
Cancer Stem Cells ◽  
Tumour Cells ◽  
Double Network

scholarly journals In vitro models of cancer stem cells and clinical applications

BMC Cancer ◽  
2016 ◽  
Vol 16 (S2) ◽  
Author(s):  
Sara S. Franco ◽  
Karolina Szczesna ◽  
Maria S. Iliou ◽  
Mohammed Al-Qahtani ◽  
Ali Mobasheri ◽  
...  
Keyword(s):  
Stem Cells ◽  
Cancer Stem Cells ◽  
In Vitro Models ◽  
Clinical Applications

scholarly journals Paclitaxel-Based Chemotherapy Targeting Cancer Stem Cells from Mono- to Combination Therapy

Biomedicines ◽  
2021 ◽  
Vol 9 (5) ◽  
pp. 500
Author(s):  
Hend M. Nawara ◽  
Said M. Afify ◽  
Ghmkin Hassan ◽  
Maram H. Zahra ◽  
Akimasa Seno ◽  
...  
Keyword(s):  
Stem Cells ◽  
Cell Death ◽  
Cancer Stem Cells ◽  
Combination Therapy ◽  
Treatment Failure ◽  
Cancer Patients ◽  
Anticancer Drugs ◽  
Causes Of Death ◽  
Therapeutic Strategies ◽  
Clinical Applications

Paclitaxel (PTX) is a chemotherapeutical agent commonly used to treat several kinds of cancer. PTX is known as a microtubule-targeting agent with a primary molecular mechanism that disrupts the dynamics of microtubules and induces mitotic arrest and cell death. Simultaneously, other mechanisms have been evaluated in many studies. Since the anticancer activity of PTX was discovered, it has been used to treat many cancer patients and has become one of the most extensively used anticancer drugs. Regrettably, the resistance of cancer to PTX is considered an extensive obstacle in clinical applications and is one of the major causes of death correlated with treatment failure. Therefore, the combination of PTX with other drugs could lead to efficient therapeutic strategies. Here, we summarize the mechanisms of PTX, and the current studies focusing on PTX and review promising combinations.

E8. Clinical applications of circulating tumour cells

2012 ◽  
Vol 48 ◽  
pp. S18-S19
Author(s):  
Brigitte Rack ◽  
Ulrich Andergassen ◽  
Julia Neugebauer ◽  
Bernadette Jäger ◽  
Wolfgang Janni
Keyword(s):  
Clinical Applications ◽  
Tumour Cells ◽  
Circulating Tumour Cells

scholarly journals Tumor-derived spheroids: Relevance to cancer stem cells and clinical applications

2017 ◽  
Vol 108 (3) ◽  
pp. 283-289 ◽  
Author(s):  
Tatsuya Ishiguro ◽  
Hirokazu Ohata ◽  
Ai Sato ◽  
Kaoru Yamawaki ◽  
Takayuki Enomoto ◽  
...  
Keyword(s):  
Stem Cells ◽  
Cancer Stem Cells ◽  
Clinical Applications

scholarly journals Lineage tracing of Notch1-expressing cells in intestinal tumours reveals a distinct population of cancer stem cells

2018 ◽  
Author(s):  
Larissa Mourao ◽  
Guillaume Jacquemin ◽  
Mathilde Huyghe ◽  
Wojciech J. Nawrocki ◽  
Naoual Menssouri ◽  
...  
Keyword(s):  
Stem Cells ◽  
Cancer Stem Cells ◽  
Critical Role ◽  
Tumour Cells ◽  
Lineage Tracing ◽  
Intestinal Stem Cells ◽  
Cellular Targets ◽  
Transcriptional Signature ◽  
Stem Cell Populations ◽  
Notch1 Receptor

AbstractColon tumours are hierarchically organized and contain multipotent self-renewing cells, called Cancer Stem Cells (CSCs). We have previously shown that the Notch1 receptor is expressed in Intestinal Stem Cells (ISCs); given the critical role played by Notch signalling in promoting intestinal tumourigenesis, we explored Notch1 expression in tumours. Combining lineage tracing in two tumour models with transcriptomic analyses, we found that Notch1 + tumour cells are undifferentiated, proliferative and capable of indefinite self-renewal and of generating a heterogeneous clonal progeny. Molecularly, the transcriptional signature of Notch1+ tumour cells highly correlates with ISCs, suggestive of their origin from normal crypt cells. Surprisingly, Notch1+ expression labels a subset of CSCs that show reduced levels of Lgr5, a reported CSCs marker. The existence of distinct stem cell populations within intestinal tumours highlights the necessity of better understanding their hierarchy and behaviour, to identify the correct cellular targets for therapy.

Sign in / Sign up

Export Citation Format

Share Document